 |
Strongly focused on increasing value |
Stock Quote
Share Information
Press Releases
SEC Filings
Code of Conduct
Investor Kit
Biopharma Industry
Media
 |
Investors |
| Industry: | Biopharmaceutical |
| Sector: | New drug discovery |
| Fiscal year end: | September 30 |
| Shares issued and outstanding: | 26,571,574* |
| Options: | 2,275,000* |
| Warrants: | 2,500,480* |
| Fully diluted: | 31,347,054* |
| Trading symbol: | AVXL |
| 52-week range: | $1.05 - $4.75* |
| Financial statements and filings: | Anavex’s filings can be found on EDGAR. |
| Investor relations: |
(866) 505-2895 - Toll free in North America +1 (416) 489 0092 - Outside North America ir@anavex.com |
| Transfer agent: |
Nevada Agency and Trust 50 West Liberty Street, Suite 880 Reno, Nevada 89501 Tel: (775) 322-0626 Fax: (775) 322-5623 Transfer agent email: info@natco.org Resident Agent email: corpserve@natco.org Web site: www.natco.org |
* As at October 28, 2011